Health Catalyst, Inc. reported robust financial results for the third quarter ended September 30, 2024, with total revenue reaching $76.4 million. This figure surpassed the mid-point of the company's quarterly guidance, demonstrating solid performance.
Adjusted EBITDA for the quarter also exceeded expectations, coming in at $7.3 million, which was above the mid-point of the company's guidance. This strong profitability performance led Health Catalyst to raise its Adjusted EBITDA guidance for the full year 2024 by $1 million.
The company now anticipates full-year 2024 total revenue to be approximately $307 million and Adjusted EBITDA to be around $26 million. For the upcoming fourth quarter of 2024, Health Catalyst expects total revenue of approximately $81 million and Adjusted EBITDA of approximately $8 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.